lysine(6)-doxorubicin LHRH

cytotoxic LHRH agonist; less toxic than doxorubicin by itself

Also Known As:

LHRH, lysine(6)-doxorubicin; AEZS-108; AN-152; Lys(6)-LHRH-doxorubicin; ZEN-008; luteinizing hormone-releasing factor (pig), 6-(N6-(5-(2-(4- ((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)- 1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11- dioxo-2-naphthacenyl)-2-oxoethoxy)-1,5-dioxopentyl)-D- lysine)-, (2S-cis)-; zoptarelin doxorubicin

Networked: 41 relevant articles (6 outcomes, 19 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Schally, Andrew V: 22 articles (12/2017 - 09/2002)
2.	Emons, Günter: 11 articles (07/2019 - 09/2002)
3.	Gründker, Carsten: 11 articles (07/2019 - 09/2002)
4.	Nagy, Attila: 9 articles (11/2005 - 09/2002)
5.	Halmos, Gabor: 7 articles (01/2020 - 09/2003)
6.	Schally, A V: 6 articles (05/2013 - 08/2000)
7.	Sindermann, Herbert: 5 articles (01/2018 - 01/2009)
8.	Rick, Ferenc G: 5 articles (01/2016 - 07/2012)
9.	Block, Norman L: 5 articles (06/2014 - 01/2011)
10.	Szalontay, Luca: 4 articles (06/2014 - 07/2012)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2012 - "A Phase I trial assessed the maximum tolerated dose and pharmacokinetics and pharmacodynamics of AEZS-108 given once every 3 weeks in patients with gynecological cancers. " 01/01/2009 - "A recently finished phase I study assessed the dose limitations, maximum tolerated dose and pharmacokinetics of AN-152 given once every 3 weeks in patients with gynecological and breast cancers. " 01/14/2020 - "In conclusion, we show for the first time that AEZS-108 has a major impact in the regulation of angiogenesis thus plays a potential role in tumor suppression. " 07/01/2019 - "The tumor reducing effects of Zoptarelin Doxorubicin were enhanced by combination with 2DG. " 06/30/2014 - "Nude mice bearing DU-145 tumors were used to compare antitumor effects of AEZS-108 with its individual constituents or their unconjugated combination. "
2.	Prostatic Neoplasms (Prostate Cancer) 12/15/2014 - "These findings show that AEZS-108 has an acceptable safety profile and a signal of efficacy, lowering PSA in heavily pretreated patients with prostate cancer, and that internalization of AEZS-108 in prostate cancer CTCs may be a viable pharmacodynamic marker. " 10/01/2003 - "In nude mice bearing intraosseous C4-2 prostate cancers, treatment with AN-152 decreased serum PSA levels (P < 0.01) to 10.3 +/- 3.4 ng/ml from 24.8 +/- 4 ng/ml in controls, whereas DOX had no effect on PSA. " 01/01/2016 - "AEZS-108 is also being evaluated in phase I/II studies in castration resistant prostate cancer and metastatic bladder cancer. " 12/15/2014 - "This phase I study determined the maximum tolerated dose (MTD) of AEZS-108 in men with taxane- and castration-resistant prostate cancer (CRPC) while providing additional information on the safety profile and efficacy of this agent. " 12/01/2017 - "A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer."
3.	Endometrial Neoplasms (Endometrial Cancer) 06/01/2012 - "Two Phase II studies in heavily pretreated ovarian and recurrent endometrial cancers showed good clinical activity after a maximum of six courses of AEZS-108 as a single agent. " 01/01/2011 - "The toxicity, pharmacokinetics and maximum tolerated doses of AN-152 were assessed in a phase I clinical trial in women with ovarian or endometrial cancer. " 09/01/2002 - "AN-152 could be considered for targeted chemotherapy in patients with ovarian or endometrial cancers." 04/01/2005 - "Experimental study using athymic nude mice bearing xenografts of HEC-1A and RL-95-2 human endometrial cancers to assess the efficacy and toxicity of AN-152 and AN-207. " 10/01/2004 - "AN-152 is internalized through the LHRH-R and induces apoptosis in LHRH-R-positive human ovarian and endometrial cancer cell lines without activating the MDR-1 efflux pump system. "
4.	Triple Negative Breast Neoplasms 07/01/2019 - "Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells." 07/01/2019 - "Triple-negative breast cancers cell lines MDA-MB-231 and HCC1806 were treated with Zoptarelin Doxorubicin, glycolysis inhibitor 2-deoxy-D-glucose (2DG) or the combination of both agents. " 05/01/2011 - "The cytotoxic LHRH agonist AEZS-108 (AN-152) seems to be a suitable drug for an efficacious therapy for triple-negative breast cancers with little toxicity." 08/01/2012 - "AEZS-108 is therefore being considered for phase II trials in triple negative breast cancers and phase III studies in advanced endometrial cancers positive for LHRH-receptor. "
5.	Breast Neoplasms (Breast Cancer) 01/01/2006 - "A first clinical trial with AN-152 was initiated recently in breast cancer patients." 03/01/1999 - "In this study, we examined binding of AN-152 and AN-207 to membranes of human breast cancer specimens and MCF-7 and MDA-MB-231 human breast cancer lines. " 10/01/2004 - "The cytotoxic LHRH analog AN-152 induces apoptosis independent of MDR-1 in LHRH-R positive breast cancer cells. " 10/01/2004 - "We compared the effects of AN-152 and doxorubicin in human breast cancer cells. " 10/01/2004 - "Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system."

Related Drugs and Biologics

1.	Gonadotropin-Releasing Hormone (GnRH)
2.	Doxorubicin (Adriamycin)
3.	AN 207
4.	LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)
5.	taxane
6.	AN 204 (AN 201)
7.	lysine(6)-doxorubicin LHRH
8.	Messenger RNA (mRNA)
9.	ErbB Receptors (EGF Receptor)
10.	Estrogens (Estrogen)

Related Therapies and Procedures

1.	Castration
2.	Drug Therapy (Chemotherapy)
3.	Therapeutics
4.	Aftercare (After-Treatment)
5.	Intravenous Administration